Is Biochemical Relapse-free Survival After Profoundly Hypofractionated Radiotherapy Consistent with Current Radiobiological Models?

Clinical Oncology

Volumn 26, Issue 4, 2014, Pages 216-229

  Tree, A C ^a   Khoo, V S ^a,b   van As, N J ^a   Partridge, M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Hypofractionation; Prostate; Radiobiology; Stereotactic

Indexed keywords

ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOBIOLOGY; RADIOTHERAPY; RECURRENCE FREE SURVIVAL; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; BIOLOGICAL MODEL; CELL SURVIVAL; DISEASE FREE SURVIVAL; MALE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; TUMOR RECURRENCE;

CELL SURVIVAL; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOBIOLOGY;

EID: 84895499458     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.01.008     Document Type: Article

References (66)

1. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43(5):1095-1101.
2. Carlson D.J., Stewart D.J., Li X.A., et al. Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol 2004, 49(19):4477-4491.
3. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13.
4. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 2001, 51(1):213-214.
5. Proust-Lima C., Taylor J.M., Secher S., et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011, 79(1):195-201.
6. Dasu A., Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012, 51(8):963-974.
7. Miralbell R., Roberts S.A., Zubizarreta E., et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82(1):e17-e24.
8. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50(4):1021-1031.
9. Wang J.Z., Huang Z., Lo S.S., et al. A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2010, 2(39). 39ra48.
10. Park C., Papiez L., Zhang S., et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(3):847-852.
11. King C.R., Kapp D.S. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 2008, 71(2):346-350.
12. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69(4):1084-1089.
13. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63(5):1463-1468.
14. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(5):1424-1430.
15. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):11-18.
16. Rene N., Faria S., Cury F., et al. Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(3):805-810.
17. Jereczek-Fossa B.A., Zerini D., Fodor C., et al. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. Urol Oncol 2011, 29(5):523-532.
18. Zilli T., Jorcano S., Rouzaud M., et al. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. Int J Radiat Oncol Biol Phys 2011, 81(2):382-389.
19. Higgins G.S., McLaren D.B., Kerr G.R., et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006, 65(4):982-989.
20. Di Staso M., Bonfili P., Gravina G.L., et al. Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU Int 2010, 106(10):1458-1462.
21. Faria S., Dal Pra A., Cury F., et al. Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiother Oncol 2011, 101(3):486-489.
22. Fonteyne V., Soete G., Arcangeli S., et al. Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 2012, 84(4):e483-e490.
23. Junius S., Haustermans K., Bussels B., et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol 2007, 2:29.
24. Koukourakis M.I., Kyrgias G., Papadopoulou A., et al. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. Anticancer Res 2011, 31(5):1745-1751.
25. Leborgne F., Fowler J., Leborgne J.H., et al. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(3):1200-1207.
26. Lock M., Best L., Wong E., et al. A phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80(5):1306-1315.
27. Valeriani M., Monaco F., Osti M.F., et al. Hypofractionated radiotherapy with or without IGRT in prostate cancer: preliminary report of acute toxicity. Anticancer Res 2011, 31(10):3555-3558.
28. Thomson D., Merrick S., Swindell R., et al. Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity. Prostate Cancer 2012, 2012:450246.
29. Wu J.S., Brasher P.M., El-Gayed A., et al. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction. Radiother Oncol 2012, 103(2):210-216.
30. Yassa M., Fortin B., Fortin M.A., et al. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71(1):58-63.
31. Coote J.H., Wylie J.P., Cowan R.A., et al. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009, 74(4):1121-1127.
32. Arcangeli S., Strigari L., Soete G., et al. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 2009, 73(1):39-45.
33. Soete G., Arcangeli S., De Meerleer G., et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006, 80(1):78-81.
34. Arcangeli G., Fowler J., Gomellini S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1013-1021.
35. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13(1):43-54.
36. Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3.
37. Madsen B.L., His R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67(4):1099-1105.
38. King C.R., Brooks J.D., Gill H., et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):877-882.
39. Jabbari S., Weinberg V.K., Kaprealian T., et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82(1):228-234.
40. Kang J.K., Cho C.K., Choi C.W., et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011, 97(1):43-48.
41. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29(15):2020-2026.
42. McBride S.M., Wong D.S., Dombrowski J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011.
43. Tang C.I., Loblaw D.A., Cheung P., et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol) 2008, 20(10):729-737.
44. Lee Y.H., Son S.H., Yoon S.C., et al. Stereotactic body radiotherapy for prostate cancer: a preliminary report. Asia Pacific J Clin Oncol 2012.
45. King C.R., Freeman D., Kaplan I., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013, 109(2):217-221.
46. Katz A. Five-year biochemical control rates for stereotactic body radiotherapy for organ confined prostate cancer: a multi-institutional pooled analysis. Oral Presentation at ASTRO Annual Meeting 2012 2012, 84(3 Suppl. 1):s147-s148.
47. Katz A.J., Santoro M., Ashley R., et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1.
48. Meier R., Kaplan I., Beckman A., et al. Stereotactic body radiation therapy for intermediate-risk organ- confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study 2012, Presented at the ASTRO annual meeting.
49. Townsend N.C., Huth B.J., Ding W., et al. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2011, 34(1):6-10.
50. Katz A.J., Santoro M., Diblasio F., et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013, 8(1):118.
51. Loblaw A., Cheung P., D'Alimonte L., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013.
52. Haustermans K.M., Hofland I., Van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37(5):1067-1070.
53. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79(2):363-370.
54. King C.R., Mayo C.S. Is the prostate a/b ratio of 1.5 from Brenner & Hall a modeling artifact?. Int J Radiat Oncol Biol Phys 2000, 47(2):536-537.
55. Shaffer R., Pickles T., Lee R., et al. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure. Int J Radiat Oncol Biol Phys 2011, 79(4):1029-1036.
56. Nickers P., Hermesse J., Deneufbourg J.M., et al. Which alpha/beta ratio and half-time of repair are useful for predicting outcomes in prostate cancer?. Radiother Oncol 2010, 97(3):462-466.
57. Marzi S., Saracino B., Petrongari M.G., et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 2009, 28:117.
58. Tucker S.L., Thames H.D., Michalski J.M., et al. Estimation of alpha/beta for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 2011, 81(2):600-605.
59. Marks L.B., Carroll P.R., Dugan T.C., et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995, 31(5):1257-1280.
60. Steel G.G. Basic clinical radiobiology 2002, CRC press, Boca Raton, Florida, USA. 3rd ed.
61. Majewski W., Maciejewski B., Majewski S., et al. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004, 60(1):60-70.
62. Heemsbergen W.D., Al-Mamgani A., Witte M.G., et al. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 2010, 78(1):19-25.
63. Zumsteg Z.S., Spratt D.E., Pei X., et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013, 85(4):1012-1017.
64. The PACE trial. http://www.clinicaltrials.gov/ct2/show/NCT01584258.
65. Tree A.C., Alexander E.J., Van As N.J., et al. Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?. Clin Oncol (R Coll Radiol) 2013, 25(8):483-498.
66. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004, 60(4):1013-1015.